Genmab licenses Bionomics angiogenesis targets
14 February, 2006 by Ruth BeranDanish biotech Genmab has acquired exclusive worldwide rights to angiogenesis targets identified by Adelaide-based Bionomics (ASX:BNO).
Resonance technology gets regulatory support
13 February, 2006 by Helen SchullerAustralian and European authorities have eased the regulatory pathway for Resonance Health (ASX:RHT), by endorsing quality assurance systems for the Perth-based firm's FerriScan technology.
Novartis, Bausch & Lomb to promote pSivida blindness treatment
10 February, 2006 by Helen SchullerPerth-based bio-nanotech company pSivida's (ASX:PSD, NASDAQ:PSDV, Xetra:PSI) Retisert will be co-promoted in the US by Novartis Ophthalmics.
Solagran's liver treatment 'fast tracked' in Russia
10 February, 2006 by Helen SchullerMelbourne-base Solagran has been granted Russian approval to register Ropren, the finished form of Bioeffective R, as a new medicine for the treatment for chronic liver disease.
Biotech Capital reduces stake in C3
10 February, 2006 by Ruth BeranBioTech Capital (ASX:BTC) has reduced its shareholding in Clinical Cell Culture (ASX:CCE, C3) from about 19 per cent to 12 per cent.
In brief: Benitec, Biota, Eqitx
09 February, 2006 by Ruth BeranBenitec (ASX:BLT) has appointed former Axon Instruments VP Michael Catelani as executive director and Boron Molecular founder Peter Francis as non-executive director.
National bioinformatics network gathers speed
09 February, 2006 by Helen SchullerA national bioinformatics network has been established following a $2.2 million grant from the National Health and Medical Research Council of Australia.
Avexa, MNLpharma sign licence agreement
08 February, 2006 by Ruth BeranAvexa (ASX:AVX) has signed an exclusive licence agreement allowing the Melbourne-based company to develop and commercialise a number of HIV integrase inhibitors discovered from UK-based MNLpharma's Phytopure library.
Biotech stocks fall in January
08 February, 2006 by Ruth BeranBiotechnology stocks have continued to underperform in January -- with the Intersuisse biotechnology index sliding by 0.9 per cent.
UQ team to test therapeutic HPV vaccine
08 February, 2006 by Graeme O'NeillA research team at the University of Queensland, headed by Prof Ian Frazer, is said to have developed a new, therapeutic vaccine for genital warts, and is about to begin phase II trials in Australia and China.
Eqitx CEO says 'no cash flow issues'
07 February, 2006 by Helen SchullerMelbourne-based Eqitx (ASX:EQX) was asked by the ASX last week to explain its financial position following the announcement it had invested a further $500,000 to increase its equity in vaccine developer VacTX.
Over the counter, into the black
07 February, 2006 by Helen SchullerSingapore-based, ASX-listed Rockeby Biomed (ASX:RBY) has changed its focus and managing director Dr Sze Wee Tan has a positive outlook for this year. Helen Schuller reports.
Why Chance takes no chances on GM
07 February, 2006 by Graeme O'NeillWestern Australia's agriculture minister, Kim Chance, is taking what many are now seeing as an overly cautious stance on biotechnology. Graeme O'Neill reports.
Industry groups warn PBS changes dangerous for biotech
07 February, 2006 by Ruth BeranWidely-touted changes to Australia's Pharmaceutical Benefits Scheme (PBS) could cost the biotech industry more than AUD$300 million in investment annually, according to AusBiotech.
Local councils to join Victorian biotech industry
07 February, 2006 by Ruth BeranA new study identifying ways that local government can assist the biotech industry was launched by Victorian minister for innovation John Brumby yesterday.
